ESPR
Esperion Therapeutics, Inc. Healthcare - Drug Manufacturers - Specialty & Generic Investor Relations →
Esperion Therapeutics, Inc. (ESPR) closed at $3.11 as of 2026-05-01, trading 7.5% above its 200-week moving average of $2.89. The stock moved further from the line this week, up from -34.4% last week. The 14-week RSI sits at 50, indicating neutral momentum.
A big jump in activity this week — 7.3x the usual volume, and the price went up. Significantly more people than usual decided to buy. This kind of surge, especially on a stock already below its 200-week average, can be an early sign that sentiment is shifting.
Over the past 622 weeks of data, ESPR has crossed below its 200-week moving average 15 times. On average, these episodes lasted 26 weeks. Historically, investors who bought ESPR at the start of these episodes saw an average one-year return of +110.6%.
With a market cap of $801 million, ESPR is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. The stock trades at -2.5x book value.
Share count has increased 228.8% over three years, indicating dilution.
Over the past 11.9 years, a hypothetical investment of $100 in ESPR would have grown to $20, compared to $450 for the S&P 500. ESPR has returned -12.8% annualized vs 13.5% for the index, underperforming the broader market over this period.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: ESPR vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After ESPR Crosses Below the Line?
Across 14 historical episodes, buying ESPR when it crossed below its 200-week moving average produced an average return of +50.7% after 12 months (median -6.0%), compared to +20.5% for the S&P 500 over the same periods. 46% of those episodes were profitable after one year. After 24 months, the average return was -38.5% vs +35.5% for the index.
Each line shows $100 invested at the moment ESPR crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
ESPR has crossed below its 200-week MA 15 times with an average 1-year return of +110.6% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jun 2014 | Jun 2014 | 2 | 2.6% | +589.7% | -79.1% |
| Jul 2014 | Jul 2014 | 2 | 8.6% | +577.0% | -78.7% |
| Sep 2014 | Sep 2014 | 1 | 1.0% | +195.1% | -79.4% |
| Sep 2015 | Feb 2017 | 74 | 67.9% | -48.3% | -88.4% |
| Mar 2017 | Mar 2017 | 1 | 17.9% | +223.3% | -86.9% |
| May 2018 | Jul 2018 | 6 | 6.9% | +39.4% | -91.7% |
| Oct 2018 | Oct 2018 | 1 | 1.4% | -4.6% | -92.6% |
| Dec 2018 | Jan 2019 | 3 | 7.4% | +37.3% | -92.1% |
| Aug 2019 | Oct 2019 | 7 | 6.8% | -12.6% | -91.6% |
| Nov 2019 | Nov 2019 | 1 | 0.3% | -33.2% | -91.8% |
| Mar 2020 | May 2020 | 8 | 26.0% | -11.9% | -91.0% |
| May 2020 | Jun 2020 | 1 | 0.7% | -53.0% | -92.7% |
| Jul 2020 | Nov 2025 | 279 | 95.6% | -61.0% | -92.2% |
| Jan 2026 | Jan 2026 | 1 | 2.1% | N/A | +2.3% |
| Mar 2026 | Ongoing | 9+ | 34.4% | Ongoing | +14.3% |
| Average | 26 | — | +110.6% | — |
Frequently Asked Questions
Is ESPR below its 200-week moving average?
No. Esperion Therapeutics, Inc. (ESPR) is currently 7.5% above its 200-week moving average of $2.89. It would need to fall to $2.89 to cross below the line.
What is ESPR's 200-week moving average price?
Esperion Therapeutics, Inc.'s 200-week moving average is $2.89 as of 2026-05-01. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when ESPR drops below its 200-week moving average?
ESPR has crossed below its 200-week moving average 15 times in our data. On average, buying at that moment produced a one-year return of +110.6%. These dips have historically been decent entry points. These episodes lasted 26 weeks on average.
Is ESPR a good value right now?
Here's what our data says about ESPR as of 2026-05-01: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 50. Free cash flow is currently negative. Price-to-book is -2.5x. This is not a buy or sell recommendation — always do your own research.
How does ESPR compare to the S&P 500?
Over the past 11.9 years, $100 invested in ESPR would have grown to $20, compared to $450 for the S&P 500. That's -12.8% annualized vs 13.5% for the index. ESPR has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-05-01